Trial Profile
Phase II trial of motexafin gadolinium [Xcytrin] for treatment of metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2016
Price :
$35
*
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 03 Nov 2005 New trial record.